Pre-diabetes, insulin resistance, inflammation and CVD risk
Pre-diabetes, insulin resistance, inflammation and CVD risk
复制标题
DOI：
10.1016/s0168-8227(03)00122-0
复制
发表时间：
2003-07-01
影响因子：
5.1
通讯作者：
Haffner, SM
中科院分区：
文献类型：
--
作者：
Haffner, SM
越来越多的证据表明，糖尿病前期的胰岛素抵抗与其他心血管危险因素的存在和心血管疾病（CVD）发病率的增加有关。也有越来越多的证据表明，慢性亚临床炎症（如c反应蛋白（CRP）等炎症标志物）与胰岛素抵抗和胰岛素抵抗综合征的其他特征、2型糖尿病发展风险增加以及心血管事件风险增加有关。在糖尿病前期，胰岛素增敏剂可能比促分泌剂在降低心血管风险方面有更大的作用，并且已经发现格列酮可以降低糖尿病患者的CRP水平。他汀类药物也能降低CRP水平。减少心血管疾病的努力应包括加强对血糖控制、预防糖尿病发展和解决糖尿病前期心血管危险因素的重视。2003爱思唯尔爱尔兰有限公司版权所有。
There is accumulating evidence that insulin resistance in the pre-diabetic state is associated with the presence of additional cardiovascular risk factors and increased incidence of cardiovascular disease (CVD). There is also accumulating evidence indicating that chronic sub-clinical inflammation as measured by such inflammatory markers as C-reactive protein (CRP) is associated with insulin resistance and other features of the insulin resistance syndrome, increased risk of development of type 2 diabetes and increased cardiovascular event risk. Insulin-sensitizing agents may have greater effects in reducing cardiovascular risk than secretagogues in the pre-diabetic state, and glitazones have been found to decrease CRP levels in patients with diabetes. Statins also reduce CRP levels. Efforts to reduce CVD should include increased emphasis on improving glycaemic control, preventing development of diabetes and addressing cardiovascular risk factors in the pre-diabetic state. (C) 2003 Elsevier Ireland Ltd. All rights reserved.